Key result
Endothelial progenitor cells respond to cardiovascular risk factors, offering diagnostic, prognostic, and therapeutic potential in CVD.
Why the study?
The exact definition and mechanism of action of endothelial progenitor cells remain unclear despite their influence by cardiovascular risk factors and potential therapeutic implications.
This review highlights the potential role of endothelial progenitor cells in cardiovascular risk assessment and future therapeutic applications.
Supports EPC research in risk assessment; leaves open clinical use pending prospective trials.
Endothelial Progenitor Cells (EPC) were first described in 1997 and have since been the subject of numerous investigative studies exploring the potential of these cells in the process of cardiovascular damage and repair. Whilst their exact definition and mechanism of action remains unclear, they are directly influenced by different cardiovascular risk factors and have a definite role to play in defining cardiovascular risk. Furthermore, EPCs may have important therapeutic implications and further understanding of their pathophysiology has enabled us to explore new possibilities in the management of cardiovascular disease. This review article aims to provide an overview of the vast literature on EPCs in relation to clinical cardiology.
No takes yet. Share an insight, caveat, or question.
Shantsila et al. (2010) conducted a review in Cardiovascular disease. Endothelial Progenitor Cells (EPC) was evaluated. Endothelial progenitor cells are directly influenced by cardiovascular risk factors and have potential diagnostic, prognostic, and therapeutic implications in cardiovascular disease management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: